Interpretation of the 2023 Recommendation Statement by the U.S.Preventive Services Task Force on the Screening for Hypertensive Disorders of Pregnancy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
国家科技期刊平台
NETL
NSTL
万方数据
妊娠期高血压疾病(HDP)是导致全球孕产妇及围生儿死亡的主要原因之一,其发病率和死亡率呈逐年增加趋势.2023 年美国预防临床服务指南工作组通过评估最新研究证据并分析HDP筛查的获益和危害,更新发布了《妊娠期高血压疾病筛查》推荐声明(以下简称"推荐").该推荐与 2017 版推荐相比,进一步肯定了血压测量筛查HDP的重要性,肯定其具有实质性的净获益,建议在整个妊娠期测量血压以筛查HDP.本文基于《指南解读类文献报告规范的制订指南(RIGHT for INT)》,探讨分析该推荐的核心要点及其对我国全科医生的指导意义.
Hypertensive disorders of pregnancy(HDP)is one of the leading causes of maternal and perinatal mortality worldwide,with increasing incidence and mortality year by year.In 2023,the U.S.Preventive Services Task Force(USPSTF)updated the recommendation statement on screening for hypertensive disorders of pregnancy by evaluating the latest research evidence and analyzing the benefits and harms of screening for HDP.The recommendation,compared with the 2017 version,further affirms the importance of blood pressure measurement in screening for HDP,affirms substantial net benefit,and recommends blood pressure measurement throughout pregnancy to screen for HDP.This article explores and analyzes the key points of this recommendation based on the RIGHT statement for introductions and interpretations of guidelines in Chinese(RIGHT for INT)and its implications for guiding general practitioners in China.
Hypertensive disorders of pregnancyScreeningGuideline interpretationU.S.Preventive Services Task Force
国家科技期刊平台
NSTL
万方数据
